Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2313626
Max Phase: Preclinical
Molecular Formula: C28H32N6O10S
Molecular Weight: 644.66
Molecule Type: Small molecule
Associated Items:
ID: ALA2313626
Max Phase: Preclinical
Molecular Formula: C28H32N6O10S
Molecular Weight: 644.66
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: OC[C@H]1O[C@@H](S[C@@H]2O[C@H](CO)[C@H](O)[C@H](n3cc(-c4cccc(O)c4)nn3)[C@H]2O)[C@H](O)[C@@H](n2cc(-c3cccc(O)c3)nn2)[C@H]1O
Standard InChI: InChI=1S/C28H32N6O10S/c35-11-19-23(39)21(33-9-17(29-31-33)13-3-1-5-15(37)7-13)25(41)27(43-19)45-28-26(42)22(24(40)20(12-36)44-28)34-10-18(30-32-34)14-4-2-6-16(38)8-14/h1-10,19-28,35-42H,11-12H2/t19-,20-,21+,22+,23+,24+,25-,26-,27+,28+/m1/s1
Standard InChI Key: ANXXDICEZCGHTO-MQFIMZJJSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 644.66 | Molecular Weight (Monoisotopic): 644.1901 | AlogP: -0.99 | #Rotatable Bonds: 8 |
Polar Surface Area: 241.72 | Molecular Species: NEUTRAL | HBA: 17 | HBD: 8 |
#RO5 Violations: 3 | HBA (Lipinski): 16 | HBD (Lipinski): 8 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.22 | CX Basic pKa: 0.05 | CX LogP: 0.16 | CX LogD: 0.15 |
Aromatic Rings: 4 | Heavy Atoms: 45 | QED Weighted: 0.11 | Np Likeness Score: 0.06 |
1. van Hattum H, Branderhorst HM, Moret EE, Nilsson UJ, Leffler H, Pieters RJ.. (2013) Tuning the preference of thiodigalactoside- and lactosamine-based ligands to galectin-3 over galectin-1., 56 (3): [PMID:23281927] [10.1021/jm301677r] |
Source(1):